SCLX

Scilex Holding Company Announces That It Regains Nasdaq Compliance Under Listing Rule 5250(C)(1)

时间：2025-01-22 00:49:30 市场：美股综合

关联： SCLX

Scilex Holding Company Announces That It Will Be Filing Today of a Supplemental New Drug Application With the FDA for Elyxyb® in Acute Pain Indication

时间：2025-01-21 20:00:01 市场：美股

关联： SCLX

Scilex Holding Company Amends Its License Agreement With Romeg Therapeutics, Llc, for the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

时间：2025-01-17 04:38:56 市场：美股综合

关联： SCLX

Scilex Holding Company Announces Early Installment Payment on Its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation

时间：2024-12-16 22:00:01 市场：美股综合

关联： SCLX

Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering

时间：2024-12-14 01:23:24 市场：美股综合

关联： SCLX

Scilex Holding Co - Expects Nasdaq Notice for Non-Compliance Due to Q3 Form 10-Q Delay

时间：2024-11-20 19:11:05 市场：美股综合

关联： SCLX

Scilex Holding Co - Audit Committee Investigates June and September 2024 Contracts

时间：2024-11-20 19:11:05 市场：美股综合

关联： SCLX

Scilex Holding Co -on Nov 1, Got Letter From Nasdaq Notifying Co Failure to Satisfy a Continued Listing Rule or Standard

时间：2024-11-08 06:58:54 市场：美股综合

关联： SCLX

Scilex Holding Shares up 7.2% at $0.87 on Plans for Unit Including Spin off

时间：2024-10-16 21:35:15 市场：美股综合

关联： SCLX

Scilex Holding Co: Total Product Net Sales for Quarter Ended September 30, 2024 Were in Range of $12.0 Mln to $14.0 Mln

时间：2024-10-09 01:58:34 市场：美股综合

关联： SCLX